CWP
CRVS icon

Curated Wealth Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Curated Wealth Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
+15,000
New +$208K ﹤0.01% 802

Other funds holding CRVS

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AIM
Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Curated Wealth Partners's CRVS Position: Q2 2026 in Review

Curated Wealth Partners opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 15,000 shares worth $15.6K. The stake represents ﹤0.01% of the portfolio and ranks #802 among its holdings.

8 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Curated Wealth Partners held 15,000 shares of Corvus Pharmaceuticals worth $15.6K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Curated Wealth Partners position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Curated Wealth Partners's portfolio in Q2 2026, its #802 holding.
  • 8 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Curated Wealth Partners's 13F filing for Q2 2026, filed 13 Jul 2026.